Search companies

Live

Tuesday, 17 November 2026 · 565 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Actinogen Halted as It Reviews XanaMIA Alzheimer’s Trial Results

ACW: $0.045 +0.00% · MC: $182M

Actinogen Medical’s shares have been placed in a trading halt while the company reviews and analyses results from its XanaMIA Phase 2b/3 Alzheimer’s trial. The halt is expected to last until a material announcement or no later than Tuesday, 17 November.

Source announcements: 2026-11-13 09:22 to 2026-11-13 09:25 Sydney time
Story updated 2026-11-13 09:29 Sydney time
SourcesRequest for Trading HaltTrading Halt
Comments